Injectable Contraceptives Market Analysis

Based on type, the injectable contraceptives market is segmented into progesterone-only injectables and combined injectable contraceptives. The progesterone-only injectables segment is further bifurcated into depot medroxyprogesterone acetate and norethisterone enanthate. In 2022, the progesterone-only injectables segment accounted for the largest business share of 68.8% in the market and is expected to grow at a CAGR of 3.3% in the forecast period. This growth can be attributed to the advantages incorporated such as, high level of efficacy and reliability in preventing unintended pregnancies.

Additionally, the progesterone-only injectables are suitable for a broader range of individuals, including those who may have contraindications to estrogen-containing contraceptives due to medical conditions or lifestyle factors. Moreover, the convenience of fewer injections, typically administered every three months, is another advantage, appealing to people preferring less frequent interventions, that has led to the growth of this segment.

Based on group, the injectable contraceptives market is segmented into 15-24 years, 25-34 years, 35-44 years, and above 44 years. The 15-24 years segment accounted for the largest share in 2022 and is expected to showcase growth at a CAGR of 3.2% during the forecast period. This growth is attributed to factors such as, convenience of injections administered every few months resonates with young adults immersed in education, career pursuits, and social activities. Additionally, the high efficacy of injectable contraceptives provides reassurance against unintended pregnancies to women that are not yet prepared for the parenthood. Moreover, the injectable contraceptives offer privacy and discretion, allowing individuals in this age group to manage their reproductive health confidentially, that has led to the growth of this segment and the overall market.

Based on duration of action, the injectable contraceptives market is classified into short-acting injectable contraceptives and long-acting injectable contraceptives. In 2022, the short-acting injectable contraceptives segment accounted for the largest market revenue of USD 207.1 million and is expected to grow at a CAGR of 3.4% in the forecast period. This expansion can be attributed to factors such as convenient of administration, resonating with individuals seeking birth control that offers reliability without committing to a longer-term method.

Additionally, the short-acting injectables are well-suited for people who value minimal disruption to their routine or privacy, as they can receive injections discreetly. The manageable time frame between doses helps ensure consistent usage, making them an attractive option for those who might not want to commit to a daily routine, such factors have directly added to the growth of the segment.

Based on end-user, the injectable contraceptives market is classified into hospital, gynaecology clinics, and other end-users. In 2022, the hospital segment accounted for the largest market revenue of USD 159.7 million and is expected to grow at a CAGR of 3.1% in the forecast period. The growth of this segment can be attributed to factors such as reliability and controlled administration of injectable contraception. By getting it administered in the hospital, the involvement of medical personnel ensures accurate dosing, reducing the risk of user error and enhancing contraceptive effectiveness.

Additionally, the use of injectable contraceptives in hospitals allows for seamless integration with other reproductive health services, offering a comprehensive approach to patient care. That is directly enhancing more patients to opt for hospitals and leading to growth of this segment.

Based on the region, the injectable contraceptives market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2022, North America accounted for a revenue of USD 137.3 million, and it is expected to reach USD 186.9 million by 2032. This expansion can be attributed to factors such as, the region's well-established healthcare systems facilitate widespread access to a variety of contraceptive options, including injectables. Furthermore, the emphasis on reproductive health education and family planning initiatives contributes to a high level of awareness among individuals, enabling them to make informed contraceptive choices.

Also, the region's trained medical professionals ensure accurate administration and monitoring of injectable contraceptives, enhancing their reliability leading to growth of market in the North America.